Nuformix PLC Appointment of Dr Muhunthan Thillai (4774L)
06 Septiembre 2019 - 1:30AM
UK Regulatory
TIDMNFX
RNS Number : 4774L
Nuformix PLC
06 September 2019
6th September 2019
Nuformix plc
("Nuformix" or "the Group"),
Appointment of Dr Muhunthan Thillai to Nuformix's Scientific
Advisory Board
Nuformix, the pharmaceutical development company using cocrystal
technology to unlock the therapeutic potential of approved small
molecule drugs today announced that it has appointed Dr Muhunthan
Thillai to Nuformix's Scientific Advisory Board.
The appointment reflects progress made with Nuformix's NXP002
programme as a treatment for Idiopathic Lung Fibrosis (IPF) as it
finalises its clinical development plans. Muhunthan joins the
Scientific Advisory Board with immediate effect.
Dr. Thillai is the Lead Clinician for the Cambridge Interstitial
Lung Disease Unit, where he is also currently appointed as a
Consultant. Dr Thillai began his training in London and Oxford
where he gained Membership of the Royal College of Physicians. He
was awarded a personal Research Training Fellowship from the
Wellcome Trust. This allowed him to undertake three years of
scientific research into sarcoidosis, in which Muhunthan
specialises in addition to IPF.
He continued his medical training in lung transplantation and
pulmonary hypertension at Royal Papworth and then in respiratory
and general medicine at Addenbrooke's Hospital. He subsequently
completed an observership in sarcoidosis at the Cleveland Center in
the USA before being appointed in 2015 as a Consultant within the
Papworth Interstitial Lung Diseases Unit with a specific interest
in sarcoidosis and IPF.
Dr Muhunthan Thillai, commenting, said: "It is a pleasure to be
joining the Nuformix team at this point. The data generated to date
in human IPF tissue slices versus current therapies demonstrates
real promise in preventing disease progression and extending life
free from side effects. Current therapies lack meaningful efficacy
and their side effects can be so severe that some patients elect to
stop treatment. Nuformix's approach offers the potential to move
rapidly into clinic and allows us to explore other unmet needs in
interstitial lung disease together."
Commenting, Dr Dan Gooding, Chief Executive Officer, Nuformix,
said: "I'm delighted to announce Dr Thillai's appointment as he is
a unique individual. Muhunthan has a complete understanding of IPF
patients, from those newly diagnosed to those receiving lung
transplants at end stage and runs the UK's second largest IPF
patient clinic at Royal Papworth. His in-depth understanding of
patients' needs and the short-comings of existing therapies will
enable Nuformix to identify how our NXP002 programme can offer
greatest benefit for his patients. Muhunthan has already
contributed to numerous IPF clinical studies and is currently
developing new technologies and novel imaging biomarkers that
improve assessment of disease progression. On top of this, he is
highly respected by his peers and well connected with the major
academic and pharmaceutical players in IPF. Muhunthan will provide
invaluable experience in the design and execution of future
Nuformix clinical studies in IPF for our NXP002 programme."
Dr Andy Richards CBE Chair of the Nuformix Scientific Advisory
Board added: "I am excited to be working with Dr Thillai as a
member of the Nuformix SAB. It is very encouraging that the data
generated and the progress made to date for NXP002 warrant building
up clinical expertise in IPF for further development. Muhunthan,
brings deep knowledge of this important disease and his insight
into biomarkers of IPF progression will be especially invaluable
for clinical trial design. His dynamism coupled to his proximity to
the Nuformix team in his role at at Royal Papworth will facilitate
real impact on NXP002 development"
The Company has entered into an agreement with Muhunthan whereby
he will be granted options to subscribe for up to 6,000,000 new
ordinary shares of 0.1 pence in the capital of the Company,
conditional upon the achievement of various clinical development
milestones, at an exercise price of 50% of the trailing 30-day
average share price on the date of achievement of each milestone
and subject to a lock-in agreement.
Market Abuse Regulation (MAR) Disclosure. Certain information
contained in this announcement would have been deemed inside
information for the purposes of Article 7 of Regulation (EU) No
596/2014 until the publication of this announcement via a
Regulatory Information Service and accordingly, this inside
information is now considered to be in the public domain.
Enquiries:
Nuformix plc
Dr Dan Gooding, Chief Executive
Officer +44 (0)1223 627222
Optimum Strategic Communications
Mary Clark, Supriya Mathur +44 (0) 20 3950
Email: nuformix@optimumcomms.com 9144
About Nuformix plc www.nuformix.com
Nuformix is a pharmaceutical development company using cocrystal
technology to unlock the therapeutic potential of approved small
molecule drugs. Nuformix's risk-mitigated development strategy has
resulted in a pipeline of discoveries through which it has
developed and patented novel cocrystal forms of approved small
molecules.
Nuformix has created an IP portfolio of granted patents covering
cocrystal forms of five small molecule drugs. Nuformix is targeting
high-value unmet needs with its lead programmes in oncology
supportive care: NXP001 and fibrosis: NXP002.
Nuformix was established in Cambridge in 2009 and has invested
in pharmaceutical cocrystal R&D, establishing world-class
capability and know-how in cocrystal discovery and development,
yielding multiple product opportunities.
Nuformix plc shares are traded on the London Stock Exchange's
Official List under the ticker: NFX.L.
About Fibrosis
Fibrotic disease is typically associated with high patient
mortality, increasing prevalence and a lack of safe and effective
treatments. Whilst, fibrosis treatments are in their infancy the
emerging lung fibrosis market demonstrates their blockbuster
potential. Markets for other fibrotic conditions are
under-developed, with large and growing patient populations (e.g.
the global liver disease market is predicted to reach $12.1 billion
by 2022). IPF is classified as a rare disease, and presents a
global commercial market that is forecast to grow to $5bn by
2025.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCZMGGLVVKGLZG
(END) Dow Jones Newswires
September 06, 2019 02:30 ET (06:30 GMT)
Nuformix (LSE:NFX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Nuformix (LSE:NFX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024